Recent advances in drug delivery systems for glaucoma treatment

K. D. Patel; L. Barrios Silva; Y. Park; T. Shakouri; Z. Keskin-Erdogan; P. Sawadkar; K. J. Cho; J. C. Knowles; D. Y.S. Chau; H. W. Kim

doi:10.1016/j.mtnano.2022.100178

Recent advances in drug delivery systems for glaucoma treatment

K. D. Patel^*, L. Barrios Silva, Y. Park, T. Shakouri, Z. Keskin-Erdogan, P. Sawadkar, K. J. Cho, J. C. Knowles, D. Y.S. Chau, H. W. Kim^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article (Academic Journal) › peer-review

47 Citations (Scopus)

Abstract

Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision in the world, which is primarily linked with high intraocular pressure (IOP). The treatment of glaucoma is currently challenging because of the innate mechanics of ocular barriers that limit the penetration of ophthalmic drugs. To tackle this, various carriers (inorganic-, polymeric-, hydrogel-, or contact lens–based) with specialized physical and chemical properties have been intensively studied. These carrier-drug formulations have shown significant improvement in various aspects, such as ocular barriers penetration, bioavailability, sustained release of drug, tissue targeting, and lowering the IOP. The delivery systems can be administered through various routes (intravitreal or periocular injection or systemic route), enabling the drugs to reach the damaged sites and help to recover the damaged optical nerves, thus considered an effective treatment strategy for glaucoma. In this review, we thoroughly investigate the recent advances in ocular delivery formulations focusing on glaucoma, including nanocarrier types, delivery route, and the efficacy in vitro and in vivo, clinical availability, and future outlook.

Original language	English
Article number	100178
Journal	Materials Today Nano
Volume	18
DOIs	https://doi.org/10.1016/j.mtnano.2022.100178
Publication status	Published - Jun 2022

Bibliographical note

Funding Information:
The authors would like to thank the National Research Foundation of Korea for providing financial support for program for UCL Eastman-Korea Dental Medicine Innovation Centre; 2018K1A4A3A0106425), and other NRF (2021R1I1A1A01050661, 2020R11A1A01071828, 2021R1A5A2022318) fundings. The Lady Barrios Silva (LSB) acknowledges support by the London Interdisciplinary Bioscience PhD Consortium (LIDo) and the Biotechnology and Biological Science Research Council (BBSRC) [Grant number BB/M009513/1]. The Zalike Keskin-Erdogan acknowledges the Turkish Ministry of National Education with the awarded scholarship of Selection and Placement of Students to be sent abrod for post graduate studies (YLSY).

Funding Information:
The authors would like to thank the National Research Foundation of Korea for providing financial support for program for UCL Eastman-Korea Dental Medicine Innovation Centre ; 2018K1A4A3A0106425 ), and other NRF ( 2021R1I1A1A01050661 , 2020R11A1A01071828 , 2021R1A5A2022318 ) fundings. The Lady Barrios Silva (LSB) acknowledges support by the London Interdisciplinary Bioscience PhD Consortium (LIDo) and the Biotechnology and Biological Science Research Council (BBSRC) [Grant number BB/M009513/1]. The Zalike Keskin-Erdogan acknowledges the Turkish Ministry of National Education with the awarded scholarship of Selection and Placement of Students to be sent abrod for post graduate studies (YLSY).

Publisher Copyright:
© 2022 Elsevier Ltd

Keywords

Contact lens
Glaucoma
Hydrogel
Nanocarriers
Ocular drug delivery

Access to Document

10.1016/j.mtnano.2022.100178

https://discovery.ucl.ac.uk/id/eprint/10144063/

Handle.net

Persistent link

Cite this

@article{0a64dce344594711bfcefd8583d96a07,

title = "Recent advances in drug delivery systems for glaucoma treatment",

abstract = "Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision in the world, which is primarily linked with high intraocular pressure (IOP). The treatment of glaucoma is currently challenging because of the innate mechanics of ocular barriers that limit the penetration of ophthalmic drugs. To tackle this, various carriers (inorganic-, polymeric-, hydrogel-, or contact lens–based) with specialized physical and chemical properties have been intensively studied. These carrier-drug formulations have shown significant improvement in various aspects, such as ocular barriers penetration, bioavailability, sustained release of drug, tissue targeting, and lowering the IOP. The delivery systems can be administered through various routes (intravitreal or periocular injection or systemic route), enabling the drugs to reach the damaged sites and help to recover the damaged optical nerves, thus considered an effective treatment strategy for glaucoma. In this review, we thoroughly investigate the recent advances in ocular delivery formulations focusing on glaucoma, including nanocarrier types, delivery route, and the efficacy in vitro and in vivo, clinical availability, and future outlook.",

keywords = "Contact lens, Glaucoma, Hydrogel, Nanocarriers, Ocular drug delivery",

author = "Patel, \{K. D.\} and \{Barrios Silva\}, L. and Y. Park and T. Shakouri and Z. Keskin-Erdogan and P. Sawadkar and Cho, \{K. J.\} and Knowles, \{J. C.\} and Chau, \{D. Y.S.\} and Kim, \{H. W.\}",

note = "Funding Information: The authors would like to thank the National Research Foundation of Korea for providing financial support for program for UCL Eastman-Korea Dental Medicine Innovation Centre; 2018K1A4A3A0106425), and other NRF (2021R1I1A1A01050661, 2020R11A1A01071828, 2021R1A5A2022318) fundings. The Lady Barrios Silva (LSB) acknowledges support by the London Interdisciplinary Bioscience PhD Consortium (LIDo) and the Biotechnology and Biological Science Research Council (BBSRC) [Grant number BB/M009513/1]. The Zalike Keskin-Erdogan acknowledges the Turkish Ministry of National Education with the awarded scholarship of Selection and Placement of Students to be sent abrod for post graduate studies (YLSY). Funding Information: The authors would like to thank the National Research Foundation of Korea for providing financial support for program for UCL Eastman-Korea Dental Medicine Innovation Centre ; 2018K1A4A3A0106425 ), and other NRF ( 2021R1I1A1A01050661 , 2020R11A1A01071828 , 2021R1A5A2022318 ) fundings. The Lady Barrios Silva (LSB) acknowledges support by the London Interdisciplinary Bioscience PhD Consortium (LIDo) and the Biotechnology and Biological Science Research Council (BBSRC) [Grant number BB/M009513/1]. The Zalike Keskin-Erdogan acknowledges the Turkish Ministry of National Education with the awarded scholarship of Selection and Placement of Students to be sent abrod for post graduate studies (YLSY). Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = jun,

doi = "10.1016/j.mtnano.2022.100178",

language = "English",

volume = "18",

journal = "Materials Today Nano",

issn = "2588-8420",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Recent advances in drug delivery systems for glaucoma treatment

AU - Patel, K. D.

AU - Barrios Silva, L.

AU - Park, Y.

AU - Shakouri, T.

AU - Keskin-Erdogan, Z.

AU - Sawadkar, P.

AU - Cho, K. J.

AU - Knowles, J. C.

AU - Chau, D. Y.S.

AU - Kim, H. W.

N1 - Funding Information: The authors would like to thank the National Research Foundation of Korea for providing financial support for program for UCL Eastman-Korea Dental Medicine Innovation Centre; 2018K1A4A3A0106425), and other NRF (2021R1I1A1A01050661, 2020R11A1A01071828, 2021R1A5A2022318) fundings. The Lady Barrios Silva (LSB) acknowledges support by the London Interdisciplinary Bioscience PhD Consortium (LIDo) and the Biotechnology and Biological Science Research Council (BBSRC) [Grant number BB/M009513/1]. The Zalike Keskin-Erdogan acknowledges the Turkish Ministry of National Education with the awarded scholarship of Selection and Placement of Students to be sent abrod for post graduate studies (YLSY). Funding Information: The authors would like to thank the National Research Foundation of Korea for providing financial support for program for UCL Eastman-Korea Dental Medicine Innovation Centre ; 2018K1A4A3A0106425 ), and other NRF ( 2021R1I1A1A01050661 , 2020R11A1A01071828 , 2021R1A5A2022318 ) fundings. The Lady Barrios Silva (LSB) acknowledges support by the London Interdisciplinary Bioscience PhD Consortium (LIDo) and the Biotechnology and Biological Science Research Council (BBSRC) [Grant number BB/M009513/1]. The Zalike Keskin-Erdogan acknowledges the Turkish Ministry of National Education with the awarded scholarship of Selection and Placement of Students to be sent abrod for post graduate studies (YLSY). Publisher Copyright: © 2022 Elsevier Ltd

PY - 2022/6

Y1 - 2022/6

N2 - Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision in the world, which is primarily linked with high intraocular pressure (IOP). The treatment of glaucoma is currently challenging because of the innate mechanics of ocular barriers that limit the penetration of ophthalmic drugs. To tackle this, various carriers (inorganic-, polymeric-, hydrogel-, or contact lens–based) with specialized physical and chemical properties have been intensively studied. These carrier-drug formulations have shown significant improvement in various aspects, such as ocular barriers penetration, bioavailability, sustained release of drug, tissue targeting, and lowering the IOP. The delivery systems can be administered through various routes (intravitreal or periocular injection or systemic route), enabling the drugs to reach the damaged sites and help to recover the damaged optical nerves, thus considered an effective treatment strategy for glaucoma. In this review, we thoroughly investigate the recent advances in ocular delivery formulations focusing on glaucoma, including nanocarrier types, delivery route, and the efficacy in vitro and in vivo, clinical availability, and future outlook.

AB - Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision in the world, which is primarily linked with high intraocular pressure (IOP). The treatment of glaucoma is currently challenging because of the innate mechanics of ocular barriers that limit the penetration of ophthalmic drugs. To tackle this, various carriers (inorganic-, polymeric-, hydrogel-, or contact lens–based) with specialized physical and chemical properties have been intensively studied. These carrier-drug formulations have shown significant improvement in various aspects, such as ocular barriers penetration, bioavailability, sustained release of drug, tissue targeting, and lowering the IOP. The delivery systems can be administered through various routes (intravitreal or periocular injection or systemic route), enabling the drugs to reach the damaged sites and help to recover the damaged optical nerves, thus considered an effective treatment strategy for glaucoma. In this review, we thoroughly investigate the recent advances in ocular delivery formulations focusing on glaucoma, including nanocarrier types, delivery route, and the efficacy in vitro and in vivo, clinical availability, and future outlook.

KW - Contact lens

KW - Glaucoma

KW - Hydrogel

KW - Nanocarriers

KW - Ocular drug delivery

UR - https://www.scopus.com/pages/publications/85126311914

U2 - 10.1016/j.mtnano.2022.100178

DO - 10.1016/j.mtnano.2022.100178

M3 - Review article (Academic Journal)

AN - SCOPUS:85126311914

SN - 2588-8420

VL - 18

JO - Materials Today Nano

JF - Materials Today Nano

M1 - 100178

ER -

Recent advances in drug delivery systems for glaucoma treatment

Abstract

Bibliographical note

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this